Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock. This study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited. The study aims to answer the question: "Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?" The study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.
Sponsor: Ottawa Heart Institute Research Corporation
You may qualify if…
- ✓ 1. Participants or substitute decision maker is able and willing to provide written informed consent
- ✓ 2. Age ≥ 18 years
- ✓ 3. SCAI stage C or D cardiogenic shock with persistent inotrope/vasopressor/non-durable mechanical support or unable to wean ventilatory support due to pulmonary edema for 24 hours prior to randomization
- ✓ 4. Greater than or equal to 3+ MR as determined by a study center's transesophageal echocardiogram (TEE)
- ✓ 5. In the opinion of the study center's heart team the participant is anatomically eligible for TMVr with the potential to achieve \<3+ MR
You may not qualify if…
- ✕ 1. Unwilling or unable to obtain informed consent from the participant or substitute decision maker
- ✕ 2. Revascularization of coronary artery disease performed in the 48 hours prior to randomization
- ✕ 3. If the mechanism of MR is deemed to be degenerative, in the opinion of the heart team the participant is eligible for surgical intervention
- ✕ 4. Prior mitral valve leaflet surgery or implanted mitral valve prosthesis (excluding ring)
- ✕ 5. Echocardiographic evidence of left sided intracardiac mass or thrombus
- ✕ 6. Diagnosis of active infective endocarditis
- ✕ 7. Transesophageal echocardiogram is contraindicated
- ✕ 8. Mitral valve anatomy deemed contraindication to TMVr implantation that cannot be addressed procedurally as determined by the study center's heart team
Where it's recruiting
Rochester
Source: ClinicalTrials.gov · NCT05298124 · last updated 2026-05-06